Helicore Biopharma, Inc.
Overview
Helicore Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for obesity and related metabolic conditions. The company's lead candidate, HCR-188, is a first-in-class biologic GIP antagonist designed to bind circulating GIP ligands, aiming to improve efficacy, dosing, and tolerability of anti-obesity therapies.
Therapeutic areas
ObesityMetabolic Disorders
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Helicore Biopharma, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Related companies
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.